2-(3-methylcyclohexyl)ethan-1-amine | 1057674-38-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(3-methylcyclohexyl)ethan-1-amine
• 英文别名: 2-(3-methylcyclohexyl)ethanamine
• CAS: 1057674-38-0
• 化学式: C₉H₁₉N
• 分子量: 141.257
• InChiKey: BFZWLRTYKGGBFP-UHFFFAOYSA-N

物化性质

• 沸点：
  180.7±8.0 °C(Predicted)
• 密度：
  0.842±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  methyl 2-(2-(chloromethyl)phenyl)acetate 、 2-(3-methylcyclohexyl)ethan-1-amine 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以32%的产率得到2-(2-(3-methylcyclohexyl)ethyl)-1,4-dihydroisoquinolin-3(2H)-one
  参考文献：
  名称：

  [EN] TRNA SYNTHETASE INHIBITORS
  [FR] INHIBITEURS D'ARNT SYNTHÉTASE

  摘要：

  本文披露了一种抑制tRNA合成酶的二级胺化合物。本发明的化合物在抑制革兰氏阴性细菌中的tRNA合成酶方面是有用的，并且在杀灭革兰氏阴性细菌方面也是有用的。本发明的二级胺化合物还在结核病的治疗中是有用的。

  公开号：

  WO2019140265A1

文献信息

• Method and an apparatus for forming a lignin fraction, a lignin composition and its use
  申请人：UPM-KYMMENE CORPORATION

  公开号：US11078225B2

  公开（公告）日：2021-08-03

  The invention relates to a method and an apparatus for forming a lignin fraction from crude lignin which has been processed by means of a treatment step selected from enzymatic treatment, treatment with ionic liquid and their combinations. The method comprises treating the crude lignin (1) by a lignin liberation in at least one lignin liberation step (3), and separating a lignin fraction (6) in at least one separation step (5). Further, the invention relates to a lignin composition and its use.

  本发明涉及一种从粗木质素中提取木质素馏分的方法和设备，粗木质素是通过从酶处理、离子液体处理及其组合中选择的处理步骤进行处理的。该方法包括在至少一个木质素释放步骤 (3) 中通过木质素释放处理粗木质素 (1)，并在至少一个分离步骤 (5) 中分离出木质素馏分 (6)。此外，本发明还涉及一种木质素组合物及其用途。
• TRNA synthetase inhibitors
  申请人：President and Fellows of Harvard College

  公开号：US11261201B2

  公开（公告）日：2022-03-01

  Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

  本发明公开了抑制 tRNA 合成酶的仲胺化合物。本发明的化合物可用于抑制革兰氏阴性细菌中的 tRNA 合成酶，并可用于杀死革兰氏阴性细菌。本发明的仲胺化合物还可用于治疗结核病。
• TRNA SYNTHETASE INHIBITORS
  申请人：President and Fellows of Harvard College

  公开号：US20210053997A1

  公开（公告）日：2021-02-25

  Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.
• AUTOMATIC DEVICE CONFIGURATION
  申请人：MEDTRONIC MINIMED, INC.

  公开号：US20220031947A1

  公开（公告）日：2022-02-03

  Methods and systems are provided for configuring therapy settings of a medical device for a specific patient. Patient data input via a non-medical device can be received. A value of a total daily dose of insulin for the specific patient can be obtained from the patient data. Based upon the value of the total daily dose, a set of therapy settings for the specific patient can be computed. The medical device can be automatically programmed with the set of therapy settings to complete set up of the medical device so that the medical device is configured for the specific patient.
• AUTOMATIC DEVICE CONFIGURATION VIA A NETWORK SERVICE
  申请人：MEDTRONIC MINIMED, INC.

  公开号：US20220036992A1

  公开（公告）日：2022-02-03

  Methods and systems are provided for automatically configuring a first medical device. In accordance with the methods and the systems, a computing system can obtain prescription information for a patient. The prescription information comprises a device prescription. The computing system can transform the prescription information into first configuration data comprising therapy settings for a first medical device referenced by the device prescription. The computing system can cause automatic configuration of the first medical device based on communicating the first configuration data to the first medical device.